Transgene reports €92.8 million in liquidity as vaccine development advances
Transgene ($TNG) reported €92.8 million in cash, cash equivalents and other current financial assets at its half-year end, compared with €111.9 million at the start of the year. First-half cash burn increased to €20.3 million from €18.8 million, while its net loss narrowed to €15.7 million from €19.3 million. Management expects current resources to fund existing plans into early 2028. The company is advancing individualized cancer vaccines based on its myvac platform. TG4050’s Phase 2 study is f
0